(Q33434683)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27531679%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

title

Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27531679%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27531679%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Ulrik Lassen

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27531679%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

21

Paul G Richardson

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27531679%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

9

Antonio Palumbo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27531679%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

6

Monique C Minnema

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27531679%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

20

Henk M Lokhorst

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27531679%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

author name string

Torben Plesner

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27531679%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Hendrik-Tobias Arkenau

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27531679%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Peter Gimsing

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27531679%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Charlotte Lemech

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27531679%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Jacob P Laubach

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27531679%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Steen Lisby

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27531679%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Linda Basse

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27531679%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Jianping Wang

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27531679%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

A Kate Sasser

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27531679%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Mary E Guckert

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27531679%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Carla de Boer

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27531679%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Nushmia Z Khokhar

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27531679%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Howard Yeh

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27531679%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Pamela L Clemens

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27531679%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Tahamtan Ahmadi

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27531679%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

language of work or name

English

0 references

publication date

16 August 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27531679%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27531679%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

volume

128

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27531679%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

issue

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27531679%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

page(s)

1821-1828

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27531679%20AND%20SRC:MED&resulttype=core&format=json

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

21 March 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5054695

New mAb therapies in multiple myeloma: interference with blood transfusion compatibility testing

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5054695

Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5054695

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5054695

Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5054695

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5054695

Resolving the daratumumab interference with blood compatibility testing

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5054695

Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5054695

Current strategies for treatment of relapsed/refractory multiple myeloma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5054695

Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.).

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5054695

Management of double-refractory multiple myeloma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5054695

The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5054695

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5054695

Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5054695

Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5054695

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5054695

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5054695

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5054695

Multiple Myeloma: Diagnosis and Treatment.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5054695

Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5054695

Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5054695

Flow cytometric detection of aneuploid CD38(++) plasmacells and CD19(+) B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5054695

Clarification of the definition of complete response in multiple myeloma

31 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27531679

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1182/BLOOD-2016-07-726729

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27531679%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27531679%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

PubMed publication ID

27531679

1 reference